Based on the Carisma Therapeutics Inc. stock forecast from 2 analysts, the average analyst target price for Carisma Therapeutics Inc. is USD 9.00 over the next 12 months. Carisma Therapeutics Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Carisma Therapeutics Inc. is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Carisma Therapeutics Inc.’s stock price was USD 1.01. Carisma Therapeutics Inc.’s stock price has changed by +4.05% over the past week, +5.18% over the past month and -63.54% over the last year.
No recent analyst target price found for Carisma Therapeutics Inc.
No recent average analyst rating found for Carisma Therapeutics Inc.
Company Overview Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania. Read Less
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phas...Read More
Frequently Asked Questions About Carisma Therapeutics Inc. (CARM) Stock
Based on ratings from 2 analysts Carisma Therapeutics Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on CARM's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for CARM is USD 9.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 8.
CARM stock's Price/Earning ratio is 21.38.
Our analysis grades CARM stock's Price / Earning ratio at F. This means that CARM stock's Price/Earning ratio is above 71% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CARM may be a overvalued for its sector.
The last closing price of CARM's stock was USD 1.01.
The most recent market capitalization for CARM is USD 0.04B.
Based on targets from 2 analysts, the average taret price for CARM is projected at USD 9.00 over the next 12 months.
This means that CARM's stock price may go up by +791.09% over the next 12 months.
We can't find any ETFs which contains Carisma Therapeutics Inc.'s stock.
As per our most recent records Carisma Therapeutics Inc. has 107 Employees.
Carisma Therapeutics Inc.'s registered address is 3675 Market Street, Philadelphia, PA, United States, 19104.
You can get more information about it from Carisma Therapeutics Inc.'s website at https://www.carismatx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Carisma Therapeutics Inc. (CARM) Stock
Based on ratings from 2 analysts Carisma Therapeutics Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on CARM's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for CARM is USD 9.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 8.
CARM stock's Price/Earning ratio is 21.38.
Our analysis grades CARM stock's Price / Earning ratio at F. This means that CARM stock's Price/Earning ratio is above 71% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CARM may be a overvalued for its sector.
The last closing price of CARM's stock was USD 1.01.
The most recent market capitalization for CARM is USD 0.04B.
Based on targets from 2 analysts, the average taret price for CARM is projected at USD 9.00 over the next 12 months.
This means that CARM's stock price may go up by +791.09% over the next 12 months.
We can't find any ETFs which contains Carisma Therapeutics Inc.'s stock.
As per our most recent records Carisma Therapeutics Inc. has 107 Employees.
Carisma Therapeutics Inc.'s registered address is 3675 Market Street, Philadelphia, PA, United States, 19104.
You can get more information about it from Carisma Therapeutics Inc.'s website at https://www.carismatx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CARM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
